Clinical Trials Browser

Interventional × Adenocarcinoma × cemiplimab × Clear all

NCT05208944 2026-05-13

THIO Sequenced With Cemiplimab in Advanced NSCLC

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06205836 2026-05-06

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Colorectal Neoplasms

NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3 Recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04646005 2025-09-08

Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Phase 2 Completed

113 enrolled 18 charts

Adenocarcinoma, Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT04543071 2025-06-19

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms